SEELAS Life Sciences (SLS) - 2025 Q1 - Quarterly Results

Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update – Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients– NEW YORK, NY May 13, 2025 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical ...